BRIEF published on 04/24/2026 at 07:05, 4 months 18 days ago BB Biotech AG publie ses résultats intermédiaires du premier trimestre 2026 Perte Nette Portefeuille D'investissement Développement De Médicaments BB Biotech 1er Trimestre 2026
BRIEF published on 04/24/2026 at 07:05, 4 months 18 days ago Réalisations et évolutions stratégiques de BB Biotech au premier trimestre 2026 Valeur Nette D'actif Nouveaux Investissements Performance De BB Biotech Repositionnement De Portefeuille Inclusion De Dividendes
BRIEF published on 04/24/2026 at 07:05, 4 months 18 days ago BB Biotech Q1 2026 Achievements and Strategic Shifts Net Asset Value Portfolio Repositioning New Investments BB Biotech Performance Dividend Inclusion
PRESS RELEASE published on 04/24/2026 at 07:00, 4 months 18 days ago EQS-Adhoc: BB Biotech AG publishes its interim report BB Biotech AG publishes its interim report for the first quarter of 2026, showing a net loss of CHF 21 mn compared to CHF 241 mn in the same period of 2025 Investment Company BB Biotech AG Interim Report Results Loss
PRESS RELEASE published on 04/24/2026 at 07:00, 4 months 18 days ago BB Biotech Q1 2026: Share price outperformance, narrowing discount and active portfolio repositioning BB Biotech AG reports Q1 2026 results with share price outperformance, narrowing discount, and active portfolio repositioning. Eleven new investments made in biotech sector Share Price BB Biotech AG Investments Portfolio Repositioning Q1 2026
BRIEF published on 03/19/2026 at 17:45, 5 months 23 days ago L'assemblée générale annuelle de BB Biotech AG approuve les propositions et le dividende Stratégie D'investissement Assemblée Générale Annuelle Réélection Du Conseil D'administration Approbation Des Dividendes BB Biotech
BRIEF published on 03/19/2026 at 17:45, 5 months 23 days ago BB Biotech AG's AGM Approves Proposals and Dividend Annual General Meeting Investment Strategy Board Re-election Dividend Approval BB Biotech
PRESS RELEASE published on 03/19/2026 at 17:40, 5 months 23 days ago Shareholders at BB Biotech AG’s AGM vote in favor of all proposals and approve the dividend of CHF 2.25 per share Shareholders at BB Biotech AG's AGM approve CHF 2.25 dividend per share. Board proposals endorsed. Re-election of board members Shareholders Dividend AGM BB Biotech AG Board Proposals
BRIEF published on 02/20/2026 at 07:05, 6 months 20 days ago BB Biotech AG publie son rapport annuel 2025 Proposition De Dividende Augmentation Du Bénéfice Net BB Biotech Secteur De La Biotechnologie Rapport Annuel 2025
BRIEF published on 02/20/2026 at 07:05, 6 months 20 days ago BB Biotech AG Releases 2025 Annual Report Dividend Proposal Biotechnology Sector Net Profit Increase BB Biotech 2025 Annual Report
Published on 09/12/2026 at 02:35, 11 hours 6 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 14 hours 41 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 15 hours 36 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 16 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 20 hours 41 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 6 hours 11 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 15 hours 26 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 15 hours 31 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 17 hours 56 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 19 hours 26 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago Availability of the 2026 Interim Financial Report
